We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Efavirenz for Patients With Alzheimer's Disease (EPAD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03706885
Recruitment Status : Completed
First Posted : October 16, 2018
Last Update Posted : February 15, 2023
University Hospitals Cleveland Medical Center
Massachusetts General Hospital
Information provided by (Responsible Party):
Irina Pikuleva, PhD, Case Western Reserve University

Brief Summary:

This will be a two-center, placebo controlled blinded clinical trial to evaluate the safety and tolerability of efavirenz (EFV) in 36 clinically stable subjects with mild cognitive impairment/early dementia due to Alzheimer's Disease (AD) age ≥55 years. Of these 36 total subjects, 18 will be recruited by MGH and 18 will be recruited by UH. A subset of the subjects at MGH only will also participate in a Stable Isotope Labeling Kinetics (SILK) protocol with deuterated water (a nonhazardous substance), designed to more precisely measure EFV effects on CNS cholesterol turnover.

Each respective site's 18 total recruited individuals will be divided into 3 groups: these 3 groups will represent two particular dosages of EFV and a placebo group, respectively. In a double-blind fashion, participants will be receiving either a capsule of EFV or placebo daily for 20 weeks. At MGH only, 12 individuals (4 from each of the two EFV groups and placebo) will participate in the unique "heavy water" SILK protocol assessing the kinetics of deuterium enrichment in plasma 24-hydroxycholesterol (24-OHC). All study participants at both sites will have their blood, cerebral spinal fluid, and urine analyzed at various points throughout the study. All participants will have their DNA genotyped for APOE isoforms (E2, E3 or E4) and single nucleotide polymorphisms (SNPs) in CYP46A1 (rs754203) and CYP2B6 (rs3745274) to be used for post-hoc analysis.

Condition or disease Intervention/treatment Phase
Alzheimer Disease, Early Onset Drug: Sustiva Pill Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 5 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Only the Statistician and Pharmacists are unmasked
Primary Purpose: Other
Official Title: A Proof-of-Concept Clinical Research Study of Efavirenz in Patients With Alzheimer's Disease
Actual Study Start Date : May 5, 2018
Actual Primary Completion Date : January 28, 2022
Actual Study Completion Date : January 28, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Efavirenz

Arm Intervention/treatment
Placebo Comparator: Placebo
Treatment with placebo - 1 pill per day for 20 weeks
Drug: Sustiva Pill
One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Other Name: Efavirenz

Active Comparator: Sustiva 50mg
Treatment with Sustiva 50mg - 1 pill per day for 20 weeks
Drug: Sustiva Pill
One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Other Name: Efavirenz

Active Comparator: Sustiva 200mg
Treatment with Sustiva 200mg - 1 pill per day for 20 weeks
Drug: Sustiva Pill
One pill (Sustiva 50 mg or Sustiva 200mg or Placebo) One pill per day for 20 weeks
Other Name: Efavirenz

Primary Outcome Measures :
  1. Plasma levels of 24-hydroxycholesterol [ Time Frame: 1 year ]
    Changes in plasma 24-hydroxycholesterol (measured in ng/dL) by more or equal to 30%.

Secondary Outcome Measures :
  1. Plasma levels of deuterated 24-hydroxycholesterol [ Time Frame: 1 year ]
    Plasma appearance of deuterated 24-hydroxycholetserol (measured in ng/dL) will be measured within 14 days after a participant will drink the last portion of deuterated water in the Stable Isotope Kinetics Labeling Study.

  2. APOE isoform status (E2, E3, or E4) and presence of the SNPs rs754203 and rs3745274 in CYP46A1 and CYP2B6, respectively. [ Time Frame: 1 year ]
    Participants will be genotyped for the APOE isoform status (E2, E3, or E4) and presence of the SNPs rs754203 and rs3745274 in CYP46A1 and CYP2B6, respectively

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Between the ages of 55-85
  • Either male or female
  • Diagnosis of (a) as per below:

    a) Mild Cognitive Impairment (MCI) or early dementia due to AD as defined by (1) complaint of cognitive decline, (2) MMSE Total=16-30, (3) CDR=0.5-1

  • Fluent in English
  • Education >8 years, literate, and/or good working history that precludes consideration of mental retardation
  • Visual and auditory acuity sufficient for neuropsychological testing
  • Modified Hachinski Ischemic Score<4
  • No major health issues or diseases expected to interfere with the study
  • Willing to complete all assessments and study procedures
  • Not pregnant, lactating or of child-bearing potential (women must be >2 years post- menopausal or surgically sterile)
  • If cognitively impaired, study partner with frequent contact with patient willing to accompany patient to visits and complete partner study forms
  • No contraindication or hypersensitivity to EFV
  • Screening laboratory testing must be within normal limits or, if abnormal, must be judged to be clinically insignificant by the investigators
  • Stable use of cholinesterase inhibitor is permitted if doses are stable for 3 months prior to enrollment

Exclusion Criteria:

  • Any CNS disease other than suspected prodromal or early AD, such as clinical stroke, brain tumor, normal pressure hydrocephalus, brain tumor, multiple sclerosis, significant head trauma with persistent neurological or cognitive deficits or complaints, Parkinson's Disease, frontotemporal dementia, or other neurodegenerative diseases
  • Ongoing major and active psychiatric disorder and/or other concurrent medical condition that, in the opinion of the investigator, might compromise safety and/or compliance with study requirements.
  • History of alcohol or other substance abuse or dependence within the past two years
  • Any significant systemic illness or unstable medical condition that could affect study compliance, including a history of prolonged QTc
  • Laboratory abnormalities in B12, TSH, or other common laboratory parameters that might contribute to cognitive dysfunction
  • Current use of medications with psychoactive properties that may deleteriously affect cognition (e.g., anticholinergics, antihistamines, antipsychotics, sedative hypnotics, anxiolytics) that, in the opinion of the investigator, may deleteriously affect cognition. Use of other investigational agents one month prior to entry and for the duration of the study
  • Treatment with any of the following agents/classes within the past 3 months: simvastatin, antiepileptic agents, clopidogrel, voriconazole, systemic ketoconazole, cyclosporine, St. John's Wort.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03706885

Layout table for location information
United States, Ohio
University Hospitals Brain Health and Memory Center
Beachwood, Ohio, United States, 44122
Sponsors and Collaborators
Case Western Reserve University
University Hospitals Cleveland Medical Center
Massachusetts General Hospital
Layout table for investigator information
Principal Investigator: Irina A Pikuleva, PhD Case Western Reserve University
Publications of Results:
Other Publications:

Layout table for additonal information
Responsible Party: Irina Pikuleva, PhD, Professor, Case Western Reserve University
ClinicalTrials.gov Identifier: NCT03706885    
Other Study ID Numbers: ADDF 20160601
First Posted: October 16, 2018    Key Record Dates
Last Update Posted: February 15, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP3A Inducers